Valuation: Scinai Immunotherapeutics Ltd.

Market Cap 718K 641K 597K 543K 1.02M 69.17M 1.03M 7.21M 2.81M 35.3M 2.7M 2.64M 113M P/E 2024 *
-
P/E 2025 -0.2x
Enterprise Value 1.32M 1.18M 1.1M 1M 1.89M 128M 1.9M 13.3M 5.17M 65.09M 4.97M 4.86M 209M EV / Sales 2024
4,521,658x
EV / Sales 2025 2,346,086x
Free-Float
0.36%
Yield 2024 *
-
Yield 2025 -
1 day-5.26%
1 week-14.29%
Current month-11.27%
1 month-32.26%
3 months-53.40%
6 months-79.00%
Current year-82.31%
1 week 1.26
Extreme 1.26
1.45
1 month 1.26
Extreme 1.26
2.67
Current year 1.26
Extreme 1.26
11.2
1 year 1.26
Extreme 1.26
16.3
3 years 1.26
Extreme 1.26
89.2
5 years 1.26
Extreme 1.26
3,490
10 years 1.26
Extreme 1.26
61,999.9
Manager TitleAgeSince
Chief Executive Officer 51 01/03/2021
Director of Finance/CFO 55 31/12/2006
Chief Tech/Sci/R&D Officer - 31/12/2021
Director TitleAgeSince
Chairman 77 29/09/2019
Director/Board Member 64 23/03/2020
Director/Board Member 71 23/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
18/03/26 Other

Chief Financial Officer

35,848,348 1.0507%
18/03/26 Other

Director

57,400,000 1.6823%
18/03/26 Other

Director

60,400,000 1.7702%
Change 5-day change 1-year change 3-year change Capi.($)
-5.26%-14.29%-90.53%-98.20% 718K
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.99%-2.33%+21.89%+77.20% 56.95B
+2.84%+1.13%+5.99%+37.67% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.30%-1.57%+40.50%+105.97% 39.36B
Weighted average by Cap. +2.26%-0.46%+59.00%+137.13%

Financials

2024 2025
Net sales 0.66 0.59 0.55 0.5 0.94 63.37 0.94 6.61 2.57 32.34 2.47 2.42 103.96 1.31 1.17 1.09 0.99 1.87 126.26 1.88 13.17 5.12 64.44 4.92 4.82 207.13
Net income 4.8M 4.28M 3.99M 3.63M 6.83M 462M 6.88M 48.16M 18.74M 236M 18M 17.62M 758M -8.31M -7.41M -6.9M -6.28M -11.83M -800M -11.92M -83.42M -32.46M -408M -31.18M -30.51M -1.31B
Net Debt 122K 109K 101K 92.27K 174K 11.75M 175K 1.23M 477K 6M 458K 448K 19.28M 606K 541K 504K 458K 863K 58.36M 870K 6.09M 2.37M 29.79M 2.27M 2.23M 95.75M
Logo Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Employees
45
Date Price Change Volume
05/10/26 US$1.260 -5.26% 42,256
02/10/26 US$1.330 +1.53% 22,168
01/10/26 US$1.310 -7.75% 43,751
30/09/26 US$1.420 +0.71% 80,134
29/09/26 US$1.410 -4.08% 98,629

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCNI Stock